Antibodies against vascular endothelial growth factor receptor-1
US7972596B2 · kind B2 · utility
7Cited by
34References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 18, 2005 |
| Grant date | Jul 5, 2011 |
| Priority date | — |
| Expiry date | Dec 26, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Monoclonal antibodies that are specific for vascular endothelial growth factor receptor 1 (VEGFR-I). This invention also provides nucleotide sequences encoding and amino acid sequences comprising variable heavy and light chain immunoglobulin molecules, including sequences corresponding to the complementarity determining regions of CDR1, CDR2, and CDR3. The invention also provides methods for generation and expression of anti -VEGFR-I antibodies and methods of treating angiogenic-related disorders and reducing tumor growth by administering anti-VEGFR-I antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.